P257 Efficacy and safety up to 3 years of risankizumab in moderately to severely active ulcerative colitis patients: COMMAND interim results
E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A240.2-A241
10.1136/gutjnl-2026-bsg.373